Sugi Predict

Sugi Predict / Compounds / SCHEMBL4089866

SCHEMBL4089866

SCHEMBL4089866

CN(C)C(=O)[C@H]1CC[C@H](N)[C@H](NC(=O)OC(C)(C)C)C1

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 1/20 0.46
▸ KDM1A O60341 2/20 0.37
▸ MAOB P27338 2/20 0.36
▸ MAOA P21397 1/20 0.36
▸ NFKB1 P19838 1/20 0.35
▸ NFKB2 Q00653 1/20 0.35
▸ RELA Q04206 1/20 0.35
▸ CTSK P43235 2/20 0.35
▸ KMT2A Q03164 1/20 0.34
▸ GAA P10253 3/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ EPHX1 P07099 1/20 0.33
▸ CYP2C9 P11712 1/20 0.32
▸ HSD11B1 P28845 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31084800 1.00 BTK (0.46) BTKKDM1AMAOBMAOANFKB1
SCHEMBL31084797 1.00 BTK (0.46) BTKKDM1AMAOBMAOANFKB1
SCHEMBL31084798 1.00 BTK (0.46) BTKKDM1AMAOBMAOANFKB1
SCHEMBL31084801 1.00 BTK (0.46) BTKKDM1AMAOBMAOANFKB1
SCHEMBL15078163 1.00 BTK (0.46) BTKKDM1AMAOBMAOANFKB1
SCHEMBL31084796 1.00 BTK (0.46) BTKKDM1AMAOBMAOANFKB1
SCHEMBL31084799 1.00 BTK (0.46) BTKKDM1AMAOBMAOANFKB1
Oxalic Acid SCHEMBL29538921 0.96 BTK (0.46) BTKKDM1AMAOBMAOANFKB1
SCHEMBL16664839 0.91 BTK (0.43) BTKKDM1AMAOBMAOANFKB1
SCHEMBL1864984 0.90 BTK (0.48) BTKKDM1AMAOBMAOANFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4631932-A1 PREPARATION METHOD FOR EDOXABAN AND INTERMEDIATE THEREOF Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) 2025-10-15 — — EP claimed
CN-113945666-B Method for detecting enantiomer in toluene sulfonic acid Ai Duosha class starting material A 哈药集团技术中心 2024-07-09 — — CN claimed
EP-3752488-B1 METHOD FOR PREPARING TERT-BUTYL N-((1R,2S,5S)-2-((2-((5-CHLOROPYRIDIN-2-YL)AMINO)-2-OXOACETYL)AMINO)-5-(DIMETHYLCARBAMOYL)CYCLOHEXYL)CARBAMATE MOEHS IBERICA SL (ES) 2023-03-08 — — EP claimed
WO-2025075234-A1 NOVEL METHOD FOR PREPARING EDOXABAN 주식회사 파마코스텍 2025-04-10 — — WO disclosed
CN-117658865-A Synthesis method of ideoxaban intermediate 山东安舜制药有限公司 2024-03-08 — — CN disclosed
WO-2023223346-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF EDOXABAN INTERMEDIATE MYLAN LABORATORIES LIMITED (IN) 2023-11-23 — — WO disclosed
CN-116410128-A Method for preparing tosylate Ai Duosha class intermediate by one-pot method 江苏宇锐医药科技有限公司 2023-07-11 — — CN disclosed
CN-116178251-A Preparation method of edoxaban intermediate 上海汇伦医药股份有限公司 2023-05-30 — — CN disclosed
WO-2023073606-A1 A PROCESS FOR PREPARATION OF INTERMEDIATE OF EDOXABAN PIRAMAL PHARMA LIMITED (IN) 2023-05-04 — — WO disclosed
EP-3752488-B1 METHOD FOR PREPARING TERT-BUTYL N-((1R,2S,5S)-2-((2-((5-CHLOROPYRIDIN-2-YL)AMINO)-2-OXOACETYL)AMINO)-5-(DIMETHYLCARBAMOYL)CYCLOHEXYL)CARBAMATE MOEHS IBERICA SL (ES) 2023-03-08 — — EP disclosed
CN-111606827-B Method for preparing chiral amine intermediate of edoxaban 内蒙古京东药业有限公司 2022-10-25 — — CN disclosed
US-7342014-B2 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-11 — — US disclosed
US-20080015215-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-01-17 — — US disclosed
US-20080015215-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-01-17 — — US disclosed
US-7192968-B2 Ethylenediamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-20 — — US disclosed
US-7192968-B2 Ethylenediamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-20 — — US disclosed
US-20060252837-A1 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-11-09 — — US disclosed
US-20060004009-A1 Ethylenediamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 — — US disclosed
US-20040122063-A1 Ethylenediamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-24 — — US disclosed
EP-1270557-A1 ETHYLENEDIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-01-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004009-A1 Ethylenediamine derivatives F2, ECE1, MLLT1 BTK 1597/4885KDM1A 498/4885MAOB 1211/4885
US-20060252837-A1 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X F2, C1S, C9 BTK 1356/4885KDM1A 3525/4885MAOB 2043/4885
US-20080015215-A1 DIAMINE DERIVATIVES C9, C1S, C1R BTK 1281/4885KDM1A 3565/4885MAOB 2147/4885
US-20040122063-A1 Ethylenediamine derivatives ECE1, F2, ECE2 BTK 1123/4885KDM1A 443/4885MAOB 609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.